Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation operates an immune medicine platform that decodes the adaptive immune system to diagnose and treat diseases. The company is organized into two primary segments: the Minimal Residual Disease (MRD) business and the Immune Medicine (IM) business. In its MRD division, the company provides the clonoSEQ diagnostic test to measure residual disease burden in lymphoid malignancies, serving clinicians in healthcare settings and biopharmaceutical companies conducting clinical drug development trials. The IM business sequences, maps, and characterizes immune receptors, offering solutions such as immunosequencing services, data licensing, predictive models, and target discovery services to academic and biopharmaceutical partners.

The company operates primarily within the United States while holding international certification in Europe and licensing its technology to partner laboratories across Europe, Australia, and Japan. Its clinical testing workflows are integrated across multiple electronic medical record networks, including Epic and Flatiron Health. The provided text does not state the company's headquarters location.

Summary of the business section of Adaptive Biotechnologies's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 624 full-time employees of which 94 hold medical or doctoral degrees.”